Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PLEC | Q15149 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 12/20 | 0.49 |
| ▸ | CA1 | P00915 | 10/20 | 0.49 |
| ▸ | CA2 | P00918 | 10/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | ELF3 | P78545 | 1/20 | 0.45 |
| ▸ | MED23 | Q9ULK4 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20276070 | 0.89 | USP2 (0.58) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL12706329 | 0.89 | USP2 (0.58) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL14586590 | 0.87 | USP2 (0.55) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL22651493 | 0.86 | USP2 (0.68) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL1103795 | 0.83 | USP2 (0.69) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL16283416 | 0.82 | USP2 (0.67) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL16407441 | 0.78 | FTO (0.61) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL10098714 | 0.78 | USP2 (0.76) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL14415288 | 0.78 | FOLH1 (0.49) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL15057677 | 0.78 | USP2 (0.48) | USP2L3MBTL1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3555627-B1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20220105208-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2022-04-07 | — | — | US | disclosed |
| US-20200237936-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-07-30 | — | — | US | disclosed |
| WO-2018111989-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9963481-B2 | Chiral oligomeric pentenoate amides as bio-oligomer mimetics | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963481-B2 | Chiral oligomeric pentenoate amides as bio-oligomer mimetics | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-08 | — | — | US | disclosed |
| US-9345662-B2 | Degradable hydrogel compositions and methods | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140271488-A1 | Chiral compounds of varying conformational rigidity and methods of synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271488-A1 | Chiral compounds of varying conformational rigidity and methods of synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | disclosed |
| US-8334239-B2 | High affinity VEGF-receptor antagonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110286926-A1 | DEGRADABLE HYDROGEL COMPOSITIONS AND METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110077201-A1 | HIGH AFFINITY VEGF-RECEPTOR ANTAGONISTS | KODADEK THOMAS | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | FAP, FIBP, FRS2 | USP2 1180/4885L3MBTL1 3795/4885MEN1 1264/4885 |
| US-20140271488-A1 | Chiral compounds of varying conformational rigidity and methods of synthesis | PDE8B, PDE8A, ABCG2 | USP2 4278/4885L3MBTL1 695/4885MEN1 1065/4885 |
| US-20220105208-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | FAP, FIBP, FRS2 | USP2 1180/4885L3MBTL1 3795/4885MEN1 1264/4885 |
| US-20200237936-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | FAP, FIBP, FRS2 | USP2 1180/4885L3MBTL1 3795/4885MEN1 1264/4885 |
| US-20110077201-A1 | HIGH AFFINITY VEGF-RECEPTOR ANTAGONISTS | KDR, FLT4, FLT1 | USP2 2291/4885L3MBTL1 3686/4885MEN1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.